A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Dose Regimens of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.
Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- 电话号码:1-317-615-4559
- 邮箱:LillyTrials@Lilly.com
研究联系人备份
- 姓名:Physicians interested in becoming principal investigators please contact
- 邮箱:clinical_inquiry_hub@lilly.com
学习地点
-
-
-
Singapore、新加坡、138623
- 尚未招聘
- Lilly Centre for Clinical Pharmacology
-
接触:
- 电话号码:64139811
-
首席研究员:
- Jennifer Boon Wee
-
-
-
-
Arkansas
-
Rogers、Arkansas、美国、72758
- 尚未招聘
- Woodland Research Northwest, LLC
-
接触:
- 电话号码:479-927-3000
-
首席研究员:
- Timothy Cook
-
-
California
-
Anaheim、California、美国、92801
- 招聘中
- CenExel ACT
-
首席研究员:
- Amina Haggag
-
Los Alamitos、California、美国、90720
- 招聘中
- Collaborative Neuroscience Network - CNS
-
首席研究员:
- Steven Reynolds
-
Walnut Creek、California、美国、94598
- 招聘中
- Diablo Clinical Research, Inc.
-
首席研究员:
- Bonnie Kimmel
-
-
Florida
-
Daytona Beach、Florida、美国、32117
- 招聘中
- Fortrea Clinical Research Unit
-
接触:
- 电话号码:866-429-3700
-
首席研究员:
- Chiamaka Iheme
-
Miami、Florida、美国、33417
- 尚未招聘
- Advanced Pharma CR, LLC
-
首席研究员:
- Simon Abelson
-
Winter Park、Florida、美国、32789
- 招聘中
- Clinical Site Partners, LLC DBA CSP Orlando
-
首席研究员:
- ROBERT MEYER
-
-
Georgia
-
Columbus、Georgia、美国、31904
- 招聘中
- Centricity Research
-
首席研究员:
- Joseph Surber
-
接触:
- 电话号码:706-321-0495
-
Decatur、Georgia、美国、30030
- 招聘中
- CenExel iResearch, LLC
-
首席研究员:
- Kimball Johnson
-
-
Missouri
-
Springfield、Missouri、美国、65802
- 招聘中
- QPS
-
首席研究员:
- Leea Reed
-
接触:
- 电话号码:417-893-6161
-
-
New Jersey
-
Marlton、New Jersey、美国、08053
- 招聘中
- CenExel-HRI
-
首席研究员:
- Kyle Coupe
-
-
Ohio
-
Columbus、Ohio、美国、43212
- 招聘中
- Ohio Clinical Trials
-
首席研究员:
- Angela Eakin
-
-
Texas
-
Dallas、Texas、美国、75247
- 招聘中
- Fortrea Clinical Research Unit
-
首席研究员:
- Archie Bowie
-
San Antonio、Texas、美国、78217
- 招聘中
- Worldwide Clinical Trials, Inc.
-
首席研究员:
- Alan Hand
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participants must be 21 in Singapore.
- Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent (%) body weight change.
Part A, B, D, and E
-
Have a body mass index (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:
- hypertension
- dyslipidemia
- obstructive sleep apnea, or
- prediabetes.
Part C
- Have a BMI ≥25.0 kg/m²
- Have a diagnosis of Type 2 Diabetes (T2D) for at least 6 months.
- T2D controlled with diet and exercise alone or are on a stable dose of metformin alone, or in combination with a sodium-glucose co-transporter-2 inhibitor (SGLT-2i), for at least 3 months.
- Have a hemoglobin (HbA1c) value of ≥6.5 % and ≤10.0%.
Part D
- To qualify as Chinese for this study, the participant must be at a minimum third-generation Chinese, defined as having all 4 of the participants' biological grandparents being of exclusive Chinese descent and born in China.
Part E
- To qualify as Japanese for this study, the participant must be at a minimum third-generation Japanese, defined as having all 4 of the participants' biological grandparents being of exclusive Japanese descent and born in Japan.
Exclusion Criteria:
- Have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine (except for T2D in Part C), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part A: LY4167586
LY4167586 administered subcutaneously (SC) |
administered SC |
|
实验性的:Part B LY4167586
LY4167586 administered SC |
administered SC |
|
实验性的:Part C LY4167586
LY4167586 administered SC |
administered SC |
|
实验性的:Part D LY4167586
LY4167586 administered SC |
administered SC |
|
实验性的:Part E LY4167586
LY4167586 administered SC |
administered SC |
|
安慰剂比较:Placebo (Part A-E)
Placebo administered SC |
administered SC |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
大体时间:Baseline through Study Completion (Estimated as Week 89)
|
Baseline through Study Completion (Estimated as Week 89)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4167586
大体时间:Baseline up to Week 89
|
Baseline up to Week 89
|
|
PK: Area Under the Concentration Time Curve (AUC) of LY4167586
大体时间:Baseline up to Week 89
|
Baseline up to Week 89
|
|
Body Weight Observed Value
大体时间:Baseline up to Week 89
|
Baseline up to Week 89
|
|
Change from Baseline in Body Weight
大体时间:Baseline up to Week 89
|
Baseline up to Week 89
|
|
Percent Change from Baseline in Body Weight
大体时间:Baseline up to Week 89
|
Baseline up to Week 89
|
合作者和调查者
调查人员
- 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.